Glutamate infusion and the incidence of acute kidney injury after coronary artery bypass grafting in relation to preoperative risk and baseline kidney function

Background Acute kidney injury (AKI) is a common and serious complication after cardiac surgery, with limited preventive strategies. Glutamate supplementation may reduce AKI indirectly by enhancing recovery of post-ischaemic myocardial metabolism and function; however, its metabolic effects appear attenuated in diabetic hearts. We investigated the association between glutamate infusion and postoperative AKI in patients without diabetes mellitus undergoing coronary artery bypass grafting (CABG), according to preoperative risk and kidney function. Methods This post hoc analysis pooled data from two randomised, double-blind, placebo-controlled GLUTAMICS trials. Patients without diabetes mellitus undergoing CABG with or without concomitant valve surgery were allocated to i.v. 0.125 M L-glutamic acid or saline. AKI was defined as a postoperative increase in plasma creatinine ≥50% from baseline (RIFLE risk stage or higher) and analysed according to European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) quartiles and estimated creatinine clearance. Results Among 791 patients, 391 received glutamate and 400 received placebo. In the combined two highest EuroSCORE II quartiles, AKI incidence was lower with glutamate (8.0% vs 16.8%; relative risk [RR] 0.47; 95% confidence interval [CI] 0.27–0.84; P =0.011). Among patients with an estimated creatinine clearance of ≥50 ml min −1 , AKI occurred in 2.7% vs 9.6% (RR 0.28; 95% CI 0.14–0.58; P <0.001). No benefit was observed with severe preoperative kidney dysfunction (estimated creatinine clearance <50 ml min −1 ). Significant interactions were observed between glutamate allocation and preoperative risk ( P =0.025) and severe preoperative kidney dysfunction ( P =0.027). Conclusions Glutamate infusion was associated with a lower incidence of AKI in higher-risk patients without diabetes mellitus, particularly those without severe preoperative kidney dysfunction. These exploratory findings require prospective confirmation. Trial registration number ClinicalTrials.gov (NCT00489827 and NCT02592824).

Authors

Institutions

Publication Details

Journal
BJA Open
Published
2026-11-18
DOI
https://doi.org/10.1016/j.bjao.2026.100890
Primary Topic
Acute Kidney Injury Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glutamate infusion and the incidence of acute kidney injury after coronary artery bypass grafting in relation to preoperative risk and baseline kidney function

J Holm, Farkas B. Vánky, Rolf Svedjeholm
1 links
BJA Open
Acute Kidney Injury Research
article

Glutamate infusion and the incidence of acute kidney injury after coronary artery bypass grafting in relation to preoperative risk and baseline kidney function

J Holm, Farkas B. Vánky, Rolf Svedjeholm
article en

Abstract

Background Acute kidney injury (AKI) is a common and serious complication after cardiac surgery, with limited preventive strategies. Glutamate supplementation may reduce AKI indirectly by enhancing recovery of post-ischaemic myocardial metabolism and function; however, its metabolic effects appear attenuated in diabetic hearts. We investigated the association between glutamate infusion and postoperative AKI in patients without diabetes mellitus undergoing coronary artery bypass grafting (CABG), according to preoperative risk and kidney function. Methods This post hoc analysis pooled data from two randomised, double-blind, placebo-controlled GLUTAMICS trials. Patients without diabetes mellitus undergoing CABG with or without concomitant valve surgery were allocated to i.v. 0.125 M L-glutamic acid or saline. AKI was defined as a postoperative increase in plasma creatinine ≥50% from baseline (RIFLE risk stage or higher) and analysed according to European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) quartiles and estimated creatinine clearance. Results Among 791 patients, 391 received glutamate and 400 received placebo. In the combined two highest EuroSCORE II quartiles, AKI incidence was lower with glutamate (8.0% vs 16.8%; relative risk [RR] 0.47; 95% confidence interval [CI] 0.27–0.84; P =0.011). Among patients with an estimated creatinine clearance of ≥50 ml min −1 , AKI occurred in 2.7% vs 9.6% (RR 0.28; 95% CI 0.14–0.58; P <0.001). No benefit was observed with severe preoperative kidney dysfunction (estimated creatinine clearance <50 ml min −1 ). Significant interactions were observed between glutamate allocation and preoperative risk ( P =0.025) and severe preoperative kidney dysfunction ( P =0.027). Conclusions Glutamate infusion was associated with a lower incidence of AKI in higher-risk patients without diabetes mellitus, particularly those without severe preoperative kidney dysfunction. These exploratory findings require prospective confirmation. Trial registration number ClinicalTrials.gov (NCT00489827 and NCT02592824).

BJA OpenVol. 20
Linköping University (SE), Linköping University Hospital (SE)
Hjärt-Lungfonden
Good health and well-being
Acute Kidney Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon